Andrés Avelino Trabanco-Suárez

This inventor holds 53 USPTO granted patents and 22 published patent applications, plus 23 CIPO patents and 32 EPO patents, primarily in Metabotropic Receptor Modulators. Top assignees: Janssen Pharmaceutica Nv, Janssen Pharmaceuticals, Inc., Addex Pharma, S.a.. Active years: 2010-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrés Avelino Trabanco-Suárez. Retrieved from https://idiyas.com/inventor/andres-avelino-trabanco-suarez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 53 (Patent Applications = 22)

% Patents Active = 37.7

CIPO Patents = 23 (Patent Applications = 14)

EPO Patents = 32 (Patent Applications = 29)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 159(Granted Patents)

Forward Citations (Not Self Cited) = 79(Dec 10, 2025)

Location History:

Olias del Ray, ES (2012 - 2015)
Madrid, ES (2016)
Olias del Rey (Toledo), ES (2015 - 2018)
Toledo, ES (2011 - 2021)
Olias del Rey, ES (2010 - 2024)

Company Filing History:

27 out of 2,101

Janssen Pharmaceutica Nv

patents

26 out of 161

Janssen Pharmaceuticals, Inc.

Addex Pharmaceuticals S.a.

patents

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

Areas of Expertise:

Metabotropic Receptors

Positive Allosteric Modulators

Negative Allosteric Modulators

BACE Inhibitors

Neurological Disorders

Psychiatric Disorders

Triazole Derivatives

Pyrazole Compounds

Thiazole Compounds

Pharmacological Applications

Toledo, ES

Compound Inhibitors

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048696 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2024-07-30),

2. 11369606 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2022-06-28),

3. 11103506 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2021-08-31),

4. 11071729 - 1',3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones (2021-07-27),

5. 10604523 - 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives (2020-03-31),

6. 10584129 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2020-03-10),

7. 10537573 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2020-01-21),

8. 10519162 - 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-12-31),

9. 10512646 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2019-12-24),

10. 10112949 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2018-10-30),

11. 10106542 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2018-10-23),

12. 10106524 - 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase (2018-10-23),

13. 10071095 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders (2018-09-11),

14. 10005786 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors (2018-06-26),

15. 10005785 - Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors (2018-06-26),

Title: Andrés Avelino Trabanco-Suárez: A Pioneer in Metabotropic Glutamatergic Research

Introduction

Andrés Avelino Trabanco-Suárez, located in Toledo, Spain, is a prolific inventor with a remarkable portfolio of 32 patents to his name. His work primarily focuses on the field of metabotropic glutamatergic receptors, which play a crucial role in various neurological processes.

Latest Patents

His latest innovations involve combinations comprising positive allosteric modulators (PAMs) or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 (mGluR2) and their utilization. The inventions detail combinations that include a PAM of mGluR2 or a pharmaceutically acceptable salt/solvate of such, alongside a synaptic vesicle protein 2A (SV2A) ligand. This work holds potential therapeutic applications, contributing significantly to advancements in pharmacology and neuroscience.

Career Highlights

Andrés has had a distinguished career, with notable contributions while working at Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals, Inc. His expertise in pharmacology and drug design has significantly impacted the development of neurological therapies.

Collaborations

Collaboration has been a key aspect of Andrés’s career. He has worked alongside esteemed colleagues, including José Maria Cid-Núñez and Gary John Tresadern, sharing a vision for innovative solutions in the pharmaceutical industry.

Conclusion

Andrés Avelino Trabanco-Suárez exemplifies the spirit of innovation in the realm of metabotropic glutamatergic research. His contributions, including numerous patents and collaborations with leading professionals, continue to foster advancements in neuroscience and pharmacotherapy, paving the way for future discoveries.

Profile summary based on public USPTO records.